Replies to post #176681 on Biotech Values

[pollyvonwog]

With all due respect to Mr. Schoenebaum and Mr. Werber, I think it’s grossly premature to label MRK as the #2 HCV player based on the pill count argument, which third-party payers don’t seem to care about.

I wouldn't paid much heed to Mr. Schoenebaum who stated that MRK can finish their PH3 trials in 6 months. lol.